menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

In Breast Cancer Prevention and Screening, Trans Women Are ‘Invisible,’ Doctors Say

29 0
27.10.2026

Without high quality data and clear consensus among the limited guidance available, patients are “falling through the cracks.”

Chloe Gremory, 34, knows that at 40, she should begin getting regular mammograms.

Early breast cancer detection, which has been facilitated in the U.S. by large education campaigns, guidelines, and routine screening practices, is linked to better outcomes, including fewer breast cancer deaths and incidences of advanced cancer.

But what might seem like a routine process isn’t so simple for Gremory—because she’s one of an estimated nearly 700,000 trans women in the U.S. 

For decades, cisgender women have borne the benefits of improvements to breast cancer prevention and screening. Breast cancer screenings are procedures targeted at detecting breast cancer, including self-exams, MRIs, and, most commonly, mammograms. On average, 1 in 8 U.S. women will develop breast cancer in their lifetime. In the U.S., breast cancer is the second leading cause of cancer death among all women, and it’s the leading cause of cancer death for non-Hispanic Black women and Hispanic women. 

But trans women, who often develop more breast tissue as a result of hormone therapy, have largely been left out of those strides. And while some medical groups have tried to provide some guidance, a lack of high quality data and consensus among major cancer organizations means trans patients—and the providers who care for them—lack the information they need to make decisions about cancer prevention.

When asked if she’d feel comfortable getting screened, Gremory’s answer was a “resounding maybe.”

“I know I’d feel a lot of anxiety and want to find an explicitly trans-friendly provider for it,” she explained.

Gremory said that despite her current primary care provider being trans-friendly, they have never brought up potential breast cancer screening options or told her about the guidance. Instead, she learned what she knows from her wife. 

A lack of data on trans populations may, in part, be to blame for trans women’s disparate breast cancer screening experiences. Little is known about how high breast cancer risk even is for trans women, doctors told Rewire News Group. A 2019 study in the Netherlands, which experts say is the largest and most authoritative cohort study on this subject, placed the risk as lower than that of cis women and higher than that of cis men. 

But that’s a broad range. Compared to that 1 in 8 statistic for cis women, breast cancer in U.S. men is incredibly rare. Only about 1 in 775 men, on average, develop breast cancer in their lifetimes. This leaves standard-setters, providers, and ultimately, patients in a difficult position when deciding how to screen trans women, and nonbinary and gender-expansive people on feminizing hormones.

It’s “a lot of deducing,” said Dr. Chandler Cortina, a........

© Rewire.News